About the Authors

Janaki Amin

jamin@kirby.unsw.edu.au

Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

Mark A. Boyd

Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

Nagalingeswaran Kumarasamy

Affiliation Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India

Cecilia L. Moore

Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

Marcello H. Losso

Affiliation Hospital JM Ramos Mejia, Buenos Aires, Argentina

Chidi A. Nwizu

Affiliation Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America

Lerato Mohapi

Affiliation University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa

Stephen J. Kerr

Affiliation UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand

Annette H. Sohn

Affiliation TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand

Hedy Teppler

Affiliation Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America

Boris Renjifo

Affiliation Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America

Jean-Michel Molina

Affiliation Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

Sean Emery

Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

David A. Cooper

Affiliation The Kirby Institute, UNSW Australia, Sydney, Australia

Competing Interests

The authors have the following interests. Merck and AbbVie partly funded the study. The sponsors participated in the study design, data collection, data analysis, data interpretation, and review and approval of the report and supplied the study drug. Hedy Teppler is employed by Merck Research Laboratories, and owns stocks and shares in the company. Boris Renjifo is employed by Abbvie and may hold Abbott or AbbVie stock or options. Raltegravir is produced by Merck & Co. and Ritonavir by AbbVie. MB has received research grant support and honoraria for serving on advisory boards and educational presentations from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, and Merck. CN has served as a speaker and received honoraria from AbbVie. ML has received research grants and unrestricted educational grants from Abbott and Merck in the past 10 years. LM received travel assistance to a conference from Pfizer Pharmaceutical in 2008. J-MM has received research grants from Merck and Gilead and participated in advisory boards on antiretroviral drugs organised by Merck, Bristol-Myers Squibb, ViiV, Gilead Sciences, and Janssen Pharmaceuticals. AS is on ViiV Health's paediatric advisory board. SE has received research grant support from Abbvie, Gilead Sciences, Merck Research Laboratories, Pfizer, and ViiV Healthcare. DAC has participated on advisory boards for Merck Sharp and Dohme and AbbVie. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Sean Emery and Janaki Amin are a PLOS ONE Editorial Board members. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria.

Author Contributions

Conceived and designed the experiments: MB NK ML CN LM SK AS HT BR JM SE DC. Performed the experiments: MB NK ML CN LM DC. Analyzed the data: CM JA. Contributed reagents/materials/analysis tools: MB NK ML CN LM DC. Wrote the paper: JA MB NK CM CN LM SK AS HT JM SE.